CTKB logo

CTKB
Cytek BioSciences Inc

302
Mkt Cap
$582.33M
Volume
480,863.00
52W High
$6.18
52W Low
$2.37
PE Ratio
-8.72
CTKB Fundamentals
Price
$4.53
Prev Close
$4.62
Open
$4.64
50D MA
$4.45
Beta
1.33
Avg. Volume
810,732.76
EPS (Annual)
-$0.5209
P/B
1.70
Rev/Employee
$287,847.14
$416.61
Loading...
Loading...
News
all
press releases
Tudor Investment Corp ET AL Invests $867,000 in Cytek Biosciences, Inc. $CTKB
Tudor Investment Corp ET AL purchased a new stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the third quarter, according to the company in its most recent 13F filing...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) have received a consensus recommendation of "Hold" from the six analysts that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rati...
MarketBeat·15d ago
News Placeholder
Topline Capital Management LLC Has $24.10 Million Position in Cytek Biosciences, Inc. $CTKB
Topline Capital Management LLC raised its stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 32.7% in the third quarter, according to the company in its most recent filing with the...
MarketBeat·28d ago
News Placeholder
Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference
Cytek Biosciences (NASDAQ:CTKB) outlined its recent product launches, geographic diversification, and expectations for 2026 during a presentation and fireside chat at TD Cowen's 42nd annual...
MarketBeat·1mo ago
News Placeholder
Royce & Associates LP Increases Holdings in Cytek Biosciences, Inc. $CTKB
Royce & Associates LP boosted its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 26.9% during the 3rd quarter, according to the company in its most recent 13F filing...
MarketBeat·1mo ago
News Placeholder
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Brokerages
Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) have earned an average recommendation of "Hold" from the seven analysts that are presently covering the company, Marketbeat.com...
MarketBeat·1mo ago
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Announces Quarterly Earnings Results, Misses Estimates By $0.36 EPS
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·1mo ago
News Placeholder
Cytek Biosciences Q4 Earnings Call Highlights
Cytek Biosciences (NASDAQ:CTKB) reported fourth-quarter and full-year 2025 results on Wednesday, describing a return to growth in the back half of the year amid what management characterized as a...
MarketBeat·1mo ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -166.67% and +0.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Earnings Breakdown: Cytek Biosciences Q4
read more...
Benzinga·1mo ago
<
1
2
...
>

Latest CTKB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.